Neither remdesivir NOR hydroxychloroquine lower the risk of respiratory failure in COVID-19 patients
A new study from Oslo University Hospital, in Norway, found that neither remdesivir nor hydroxychloroquine reduced respiratory failure or lowered inflammation in COVID-19 patients.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: COVID-19 | Health | Hospitals | Hydroxychloroquine | Norway Health | Respiratory Medicine | Study